• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CASI Pharmaceuticals Inc.

    7/25/24 8:48:03 PM ET
    $CASI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CASI alert in real time by email
    SC 13G 1 tm2420246d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    CASI Pharmaceuticals, Inc.

     

    (Name of Issuer)

     

    Ordinary Shares, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    G1933S101

     

    (CUSIP Number)

     

    July 15, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

     

     

     

     

    CUSIP No. G1933S101 Page 2 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,507,040 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,507,040 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,507,040 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 134,110 ordinary shares and 159,100 ordinary shares underlying Pre Funded Warrants (“PFWs”), of which, 105,661 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,400 ordinary shares and 15,900 ordinary shares underlying PFWs, of which, 10,559 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 695,413 ordinary shares and 825,000 ordinary shares underlying PFWs, of which, 547,897 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of ordinary shares beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise.
       
    (3)This percentage is calculated based upon the sum of (i) 13,401,375 shares of the Issuer’s ordinary shares outstanding as of April 28, 2024, as reported in the Issuer’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission (the “SEC”) on May 3, 2024; (ii) 1,020,000 ordinary shares issued in the private placement of equity securities by the Issuer that closed on July 15, 2024 (the “Private Placement”); and (iii) 664,117 shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

     

    CUSIP No. G1933S101 Page 3 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,507,040 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,507,040 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,507,040 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

       

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 134,110 ordinary shares and 159,100 ordinary shares underlying PFWs, of which, 105,661 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,400 ordinary shares and 15,900 ordinary shares underlying PFWs, of which, 10,559 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 695,413 ordinary shares and 825,000 ordinary shares underlying PFWs, of which, 547,897 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of ordinary shares beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise.
       
    (3)This percentage is calculated based upon the sum of (i) 13,401,375 shares of the Issuer’s ordinary shares outstanding as of April 28, 2024, as reported in the Issuer’s Registration Statement on Form F-3 filed with the SEC on May 3, 2024; (ii) 1,020,000 ordinary shares issued in the Private Placement; and (iii) 664,117 shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

      

    CUSIP No. G1933S101 Page 4 of 17

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,507,040 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,507,040 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,507,040 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 134,110 ordinary shares and 159,100 ordinary shares underlying PFWs, of which, 105,661 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,400 ordinary shares and 15,900 ordinary shares underlying PFWs, of which, 10,559 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 695,413 ordinary shares and 825,000 ordinary shares underlying PFWs, of which, 547,897 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of ordinary shares beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise.
       
    (3)This percentage is calculated based upon the sum of (i) 13,401,375 shares of the Issuer’s ordinary shares outstanding as of April 28, 2024, as reported in the Issuer’s Registration Statement on Form F-3 filed with the SEC on May 3, 2024; (ii) 1,020,000 ordinary shares issued in the Private Placement; and (iii) 664,117 shares issuable upon the exercise of the PFWs described in Footnote 2 above.

      

     

     

     

     

    CUSIP No. G1933S101 Page 5 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,507,040 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,507,040 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,507,040 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 134,110 ordinary shares and 159,100 ordinary shares underlying PFWs, of which, 105,661 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,400 ordinary shares and 15,900 ordinary shares underlying PFWs, of which, 10,559 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 695,413 ordinary shares and 825,000 ordinary shares underlying PFWs, of which, 547,897 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of ordinary shares beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise.
       
    (3)This percentage is calculated based upon the sum of (i) 13,401,375 shares of the Issuer’s ordinary shares outstanding as of April 28, 2024, as reported in the Issuer’s Registration Statement on Form F-3 filed with the SEC on May 3, 2024; (ii) 1,020,000 ordinary shares issued in the Private Placement; and (iii) 684,110 shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

     

    CUSIP No. G1933S101 Page 6 of 17

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,507,040 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,507,040 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,507,040 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.
       
    (2)Consists of (i) 134,110 ordinary shares and 159,100 ordinary shares underlying PFWs, of which, 105,661 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,400 ordinary shares and 15,900 ordinary shares underlying PFWs, of which, 10,559 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 695,413 ordinary shares and 825,000 ordinary shares underlying PFWs, of which, 547,897 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of ordinary shares beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise.
       
    (3)This percentage is calculated based upon the sum of (i) 13,401,375 shares of the Issuer’s ordinary shares outstanding as of April 28, 2024, as reported in the Issuer’s Registration Statement on Form F-3 filed with the SEC on May 3, 2024; (ii) 1,020,000 ordinary shares issued in the Private Placement; and (iii) 684,110 shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

     

    CUSIP No. G1933S101 Page 7 of 17

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,507,040 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,507,040 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,507,040 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 134,110 ordinary shares and 159,100 ordinary shares underlying PFWs, of which, 105,661 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,400 ordinary shares and 15,900 ordinary shares underlying PFWs, of which, 10,559 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 695,413 ordinary shares and 825,000 ordinary shares underlying PFWs, of which, 547,897 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of ordinary shares beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise.

     

    (3)This percentage is calculated based upon the sum of (i) 13,401,375 shares of the Issuer’s ordinary shares outstanding as of April 28, 2024, as reported in the Issuer’s Registration Statement on Form F-3 filed with the SEC on May 3, 2024; (ii) 1,020,000 ordinary shares issued in the Private Placement; and (iii) 684,110 shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

     

    CUSIP No. G1933S101 Page 8 of 17

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1) (b) ¨

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,507,040 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,507,040 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,507,040 (2)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

     

    (2)Consists of (i) 134,110 ordinary shares and 159,100 ordinary shares underlying PFWs, of which, 105,661 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,400 ordinary shares and 15,900 ordinary shares underlying PFWs, of which, 10,559 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 695,413 ordinary shares and 825,000 ordinary shares underlying PFWs, of which, 547,897 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of ordinary shares beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise.

     

    (3)This percentage is calculated based upon the sum of (i) 13,401,375 shares of the Issuer’s ordinary shares outstanding as of April 28, 2024, as reported in the Issuer’s Registration Statement on Form F-3 filed with the SEC on May 3, 2024; (ii) 1,020,000 ordinary shares issued in the Private Placement; and (iii) 684,110 shares issuable upon the exercise of the PFWs described in Footnote 2 above.

     

     

     

     

     

    CUSIP No. G1933S101 Page 9 of 17

     

    Item 1.
      (a)

    Name of Issuer

     

    CASI Pharmaceuticals, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    1701-1702, China Central Office Tower 1

    No. 81 Jianguo Road, Chaoyang District

    Beijing, 100025

    People’s Republic of China

     
    Item 2.
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence
             
        New York Office: Palo Alto Office:  
             
        7 Bryant Park 3340 Hillview Avenue  
        23rd Floor Palo Alto, CA 94304  
        New York, NY 10018    

     
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Ordinary Shares, $0.0001 par value

     
      (e)

    CUSIP Number

     

    G1933S101

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable

     

     

     

     

     

    CUSIP No. G1933S101 Page 10 of 17

     

    Item 4. Ownership  
      (a) Amount beneficially owned:  

     

      Venrock Healthcare Capital Partners III, L.P.    1,507,040 (1)
      VHCP Co-Investment Holdings III, LLC    1,507,040 (1)
      Venrock Healthcare Capital Partners EG, L.P.    1,507,040 (1)
      VHCP Management III, LLC    1,507,040 (1)
      VHCP Management EG, LLC    1,507,040 (1)
      Nimish Shah    1,507,040 (1)
      Bong Koh    1,507,040 (1)

     

      (b) Percent of class:  

     

      Venrock Healthcare Capital Partners III, L.P.    9.99 % (2)
      VHCP Co-Investment Holdings III, LLC    9.99 % (2)
      Venrock Healthcare Capital Partners EG, L.P.    9.99 % (2)
      VHCP Management III, LLC    9.99 % (2)
      VHCP Management EG, LLC    9.99 % (2)
      Nimish Shah    9.99 % (2)
      Bong Koh    9.99 % (2)

     

      (c) Number of shares as to which the person has:  

     

        (i)     Sole power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.   0
      VHCP Co-Investment Holdings III, LLC   0
      Venrock Healthcare Capital Partners EG, L.P.   0
      VHCP Management III, LLC   0
      VHCP Management EG, LLC   0
      Nimish Shah   0
      Bong Koh   0

     

        (ii)     Shared power to vote or to direct the vote:

     

      Venrock Healthcare Capital Partners III, L.P.    1,507,040 (1)
      VHCP Co-Investment Holdings III, LLC    1,507,040 (1)
      Venrock Healthcare Capital Partners EG, L.P.    1,507,040 (1)
      VHCP Management III, LLC    1,507,040 (1)
      VHCP Management EG, LLC    1,507,040 (1)
      Nimish Shah    1,507,040 (1)
      Bong Koh    1,507,040 (1)

     

     

     

     

     

    CUSIP No. G1933S101 Page 11 of 17

     

        (iii)   Sole power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.   0
      VHCP Co-Investment Holdings III, LLC   0
      Venrock Healthcare Capital Partners EG, L.P.   0
      VHCP Management III, LLC   0
      VHCP Management EG, LLC   0
      Nimish Shah   0
      Bong Koh   0

     

        (iv)   Shared power to dispose or to direct the disposition of:

     

      Venrock Healthcare Capital Partners III, L.P.    1,507,040 (1)
      VHCP Co-Investment Holdings III, LLC    1,507,040 (1)
      Venrock Healthcare Capital Partners EG, L.P.    1,507,040 (1)
      VHCP Management III, LLC    1,507,040 (1)
      VHCP Management EG, LLC    1,507,040 (1)
      Nimish Shah    1,507,040 (1)
      Bong Koh    1,507,040 (1)

      

    (1)Consists of (i) 134,110 ordinary shares and 159,100 ordinary shares underlying PFWs, of which, 105,661 are currently exercisable held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,400 ordinary shares and 15,900 ordinary shares underlying PFWs, of which, 10,559 are currently exercisable held by VHCP Co-Investment Holdings III, LLC; and (iii) 695,413 ordinary shares and 825,000 ordinary shares underlying PFWs, of which, 547,897 are currently exercisable held by Venrock Healthcare Capital Partners EG, L.P. Under the terms of the PFWs, the Issuer may not effect the exercise of any such PFWs, and a holder will not be entitled to exercise any portion of such PFWs, if, upon giving effect to such exercise, the aggregate number of ordinary shares beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of ordinary shares outstanding immediately after giving effect to the exercise.

     

        VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    (2)This percentage is calculated based upon the sum of (i) 13,401,375 shares of the Issuer’s ordinary shares outstanding as of April 28, 2024, as reported in the Issuer’s Registration Statement on Form F-3 filed with the SEC on May 3, 2024; (ii) 1,020,000 ordinary shares issued in the Private Placement; and (iii) 664,117 shares issuable upon the exercise of the PFWs described in Footnote 1 above.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ☐

     

     

     

    CUSIP No. G1933S101 Page 12 of 17

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable

     

    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
             

     

     

     

     

    CUSIP No. G1933S101 Page 13 of 17

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 25, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

      

     

    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  

     

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

     

    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

      

     

     

     

     

    CUSIP No. G1933S101 Page 14 of 17

      

    EXHIBITS
     
    A:  Joint Filing Agreement
     
    B: Power of Attorney for Nimish Shah
     
    C: Power of Attorney for Bong Koh

     

     

     

     

      

    CUSIP No. G1933S101 Page 15 of 17

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares of CASI Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 25th day of July, 2024.

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

      

     

    VHCP Co-Investment Holdings III, LLC  
       
    By: VHCP Management III, LLC  
    Its: Manager  
       
    By: /s/ Sherman G. Souther  
      Name: Sherman G. Souther  
      Its: Authorized Signatory  

     

     

    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory

     

     

    Nimish Shah  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

     

     

    Bong Koh  
       
    /s/ Sherman G. Souther  
    Sherman G. Souther, Attorney-in-fact  

      

     

     

     

     

    CUSIP No. G1933S101 Page 16 of 17

     

    EXHIBIT B

     

    POWER OF ATTORNEY FOR NIMISH SHAH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of July, 2024.

     

    /s/ Nimish Shah  

     

     

     

    CUSIP No. G1933S101 Page 17 of 17

     

    EXHIBIT C

     

    POWER OF ATTORNEY FOR BONG KOH

     

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

     

    (i)prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

     

    (ii)take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

     

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

     

    This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

     

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 25th day of July, 2024.

     

    /s/ Bong Koh  

     

     

    Get the next $CASI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CASI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CASI Pharmaceuticals Inc.

      SC 13G/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

      10/29/24 4:05:28 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by CASI Pharmaceuticals Inc.

      SC 13D/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

      8/12/24 8:27:51 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CASI Pharmaceuticals Inc.

      SC 13G - CASI Pharmaceuticals, Inc. (0001962738) (Subject)

      7/25/24 8:48:03 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on CASI Pharma with a new price target

      BTIG Research initiated coverage of CASI Pharma with a rating of Buy and set a new price target of $4.00

      5/18/21 6:41:48 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on CASI Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.50 previously

      5/14/21 6:40:01 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on CASI Pharmaceuticals with a new price target

      Mizuho initiated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $3.80

      4/26/21 7:19:24 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

      BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the Phase 1/2 trial to evaluate the safety and tolerability of CID-103 in adult patients with chronic Immune Thrombocytopenia (ITP) in China."Dosing the first patient in our phase 1/2 study marks a significant milestone for both CID-103 program and chronic ITP patients who have limited treatment options," said Dr. Wei-Wu He, Chairman and CEO of CASI, "The rapid execution underscores our commitment to accelerating clinic

      1/6/25 8:00:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

      BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024.Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases. We just announced the Center for Drug Evaluation (CDE) of China's Nationa

      11/15/24 8:00:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

      BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2 study of CID-103 in adults patients with chronic Immune Thrombocytopenia (ITP) in China. This China study is part of the global study that was approved by the US FDA in May 2024.CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that ha

      10/24/24 8:00:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    SEC Filings

    See more
    • SEC Form 6-K filed by CASI Pharmaceuticals Inc.

      6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

      5/20/25 8:31:31 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 6-K/A filed by CASI Pharmaceuticals Inc.

      6-K/A - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

      5/20/25 8:00:22 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CASI Pharmaceuticals Inc.

      6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)

      5/16/25 8:30:18 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CASI
    Financials

    Live finance-specific insights

    See more

    $CASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CASI
    Leadership Updates

    Live Leadership Updates

    See more
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ligand Reports First Quarter 2024 Financial Results

      Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe

      5/7/24 4:00:00 PM ET
      $AMGN
      $CASI
      $JAZZ
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

      BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the United States ("US") CB-5339 Investigational New Drug ("IND") application.

      7/20/23 8:00:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Zukiwski Alexander A

      4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)

      9/9/22 4:01:37 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Huang James bought $229,662 worth of shares (55,573 units at $4.13)

      4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)

      9/8/22 6:51:39 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Huang James bought $139,036 worth of shares (37,196 units at $3.74)

      4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)

      9/2/22 7:35:18 PM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

      BEIJING, July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capi

      7/8/24 7:30:00 AM ET
      $CASI
      Biotechnology: Pharmaceutical Preparations
      Health Care